- Home
- LSF vs NRXP Comparison
LSF vs NRXP Comparison
Compare LSF & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | NRXP |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8M | 54.2M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LSF | NRXP |
|---|---|---|
| Price | $2.44 | $1.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $12.00 | ★ $31.50 |
| AVG Volume (30 Days) | 50.8K | ★ 489.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,295,137.00 | N/A |
| Revenue This Year | $15.87 | N/A |
| Revenue Next Year | $14.98 | $847.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.50 | N/A |
| 52 Week Low | $1.98 | $1.58 |
| 52 Week High | $7.94 | $3.84 |
Technical Indicators
Market Signals| Indicator | LSF | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 36.78 | 43.01 |
| Support Level | $2.46 | $1.65 |
| Resistance Level | $2.76 | $1.99 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 20.28 | 30.16 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.